ATRC AtriCure, Inc.

CIK 0001323885 18 ready 8-Ks latest May 19, 2026, 4:21 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 18

Latest filing May 19, 2026, 4:21 PM ET

Top materiality 0.78

Event mix earnings ×13 · other ×3 · other_material ×2

Sentiment 11 pos · 0 neg · 7 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for ATRC

Highest-materiality recent filing

AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook

July 29, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 9.01

Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).
Net loss $6.2M, improved $1.8M YoY; adjusted EBITDA $15.4M, up $7.6M YoY.

Read filing →

May 19, 2026, 4:21 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01

AtriCure shareholders approve share increases for 2023 Stock Incentive Plan and 2018 ESPP

Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares from 4.5M to 6M.
May 6, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q1 revenue $141.2M (+14.3%); corrects FY2026 guidance to rev $600-610M, adj EBITDA $80-82M

Q1 revenue $141.2M (+14.3% YoY); net income $0.1M, breakeven EPS.
May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

AtriCure Q1 2026 revenue $141.2M (+14.3%); net income $0.1M; adj. EBITDA $17.1M

Worldwide revenue $141.2M (+14.3% YoY); U.S. $116.2M (+14.9%), international $25.0M (+11.5%).
February 17, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M

Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 1.01 item 2.02 item 2.03 item 9.01 ◈ Material Agreements

AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M

Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).
October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 revenue $134.3M (+15.8% YoY); net loss narrows to $0.3M; raises FY2025 outlook

Revenue $134.3M, +15.8% YoY (+15.1% constant currency); US $109.3M (+14.5%), intl $25.0M (+22.0%).
October 29, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 revenue +15.8% to $134.3M, net loss narrows to $0.3M; raises 2025 outlook

Revenue of $134.3M (+15.8% YoY); U.S. $109.3M (+14.5%), international $25.0M (+22.0%).
July 29, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 9.01

AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook

Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).
May 20, 2025, 7:59 PM ET other materiality 0.40 neutral item 5.02 item 5.07 item 9.01

AtriCure shareholders approve 1.7M share increase in 2023 Stock Incentive Plan at annual meeting

Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 2.8M to 4.5M.
April 29, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

AtriCure Q1 revenue $123.6M (+13.6% YoY); net loss improves to $6.7M from $13.2M

Revenue $123.6M (+13.6% YoY; +14.1% constant currency); U.S. $101.1M (+12.1%), International $22.5M (+20.8%).
March 26, 2025, 7:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

AtriCure holds 2025 Investor Day; presentation details not provided in filing excerpt

Investor Day held March 26, 2025 at Mason, OH headquarters from 1-4 p.m. ET.
February 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

AtriCure Q4 revenue $124.3M (+16.6% YoY); guides FY25 rev $517-527M

Q4 revenue $124.3M (+16.6%); full year revenue $465.3M (+16.5%).
January 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M

Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).
October 29, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M

Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).
July 30, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share

Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).
May 14, 2024, 7:59 PM ET other material materiality 0.30 neutral item 5.02 item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×13◈ Governance Changes

AtriCure shareholders approve increase in authorized shares under 2023 Stock Incentive Plan to 2.8M

Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 1,000,000 to 2,800,000.
May 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28

Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).
February 27, 2024, 6:59 PM ET other materiality 0.20 neutral item 5.02 item 9.01

AtriCure amends 8-K to add director Shlomi Nachman to two board committees

Shlomi Nachman elected to Board on Jan 4, 2024, as previously reported.

Earnings & guidance

2026-Q1 EPS reported $0.00 filing →

Materiality & sentiment trend

Max materiality 0.78 · Median 0.70 · Most common event earnings

11 positive 0 negative 7 neutral

source · ATRC on sec.gov